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ImmunotherapyAcinetobacter baumannii has recently crossed all lines once considered harmless, pushing its way as a
nosocomial pathogen. It had acquired resistance to almost all available chemotherapies and mainly tar-
gets intensive care residents; causing pneumonia and major outbreaks with high mortality rates. This
urged the need for preventive methods, which include infection control, non-specific immune-therapy,
passive, and active immunization in order to offer vulnerable immune-compromised patients a flare in
the dark. Several attempts were done for constructing effective vaccines with promising results. These
are precisely classified, documented, and discussed in this up-to-date review.
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Hospital’s laboratories are pointing to a new emerging Gram-
negative bacilli named Acinetobacter; specifically Acinetobacter
baumannii. The bacterium affects different human organs particu-
larly the lungs, causing Ventilator-Associated Pneumonia (VAP)
[1] which usually develops to septicemia in intensive care unit(ICU) residents [2]. It mainly infects the peritoneal cavity then
rapidly disseminates to the lungs and spleen, it replicates to pro-
duce septic shock and might lead to associated bacteremia [2,3].
Infection is characterized by a rapid onset within 36 h, and pro-
gressive symptoms that leads to a mortality rate ranging from
40% to 60% [4]. Acinetobacter spp. are Gram-negative diplo-
coccobacilli, non-fermentative, and are strictly aerobic bacteria
[5]. They are catalase-positive, oxidase negative, and hard to de-
stain, thus sometimes misidentified as being Gram-positive. There-
fore, it has undergone many changes in taxonomy from Neisseri-
aceae to the family Moraxellaceae [6,7]. They are non-motile due
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ment [8]. Acinetobacter genus is pervasive in nature between soil,
water, human skin, throat, and respiratory tract colonization [9].
But this was pleaded against in the case of A. baumannii and its
two relatives (Acinetobacter calcoaceticus and Acinetobacter nosoco-
mialis) collectively known as ACB complex together with Acineto-
bacter pittii [10] that are only isolated from hospital-setting and
are outbreaks-associated [7,11,12]. Recently, two more species
were added to the ACB complex, those include Acinetobacter seifer-
tii sp. nov. [13], and Acinetobacter dijikshoornii sp. nov. [14].
Although DNA-DNA hybridization can identify Acinetobacter
genus [12], further advanced techniques are required to identify
A. baumannii down to the strain level. Such techniques include
amplified 16S ribosomal DNA restriction analysis, and high resolu-
tion fingerprint analysis [15]. However, those are complicated
methods and are not present in common laboratories. Therefore,
it is a hard mission to quickly identify A. baumannii in ICUs, and
in times of outbreaks [16].
Moreover, A. baumannii possesses special pathogenic traits such
as the ability to form biofilm, the production of siderophores, the
presence of capsular polysaccharide and fimbriae, the cell to cell
signals (Quorum Sensing), and the production of hydrolytic
enzymes [17]. These virulence features facilitate its adherence
and tolerance to desiccation on inanimate surfaces for more than
14 days [18]. All of these pathogenesis factors lead to persistent
occupancy in hospitals, increase morbidity rates, and eventually
lead to hospital cross transmission with persistent outbreaks [19].2. Epidemiology
The incidence of nosocomial infection patterns are changing
due to the emergence of new pathogens, along with changes in
the antibiograms due to antibiotics abuse [20]. Based on the
surveillance data, alerts were raised toward A. baumannii in partic-
ular due to its high persistence on inanimate objects in ICUs for
months. In addition, A. baumannii rapidly acquired resistance
against almost all potent antibiotics, thus adding days to ICU stay
[21].
Outbreaks were correlated to seasonal factors, patient cases,
and disasters times. A. baumannii was found to be more prevalent
in late summer to early winter [7] rising up to 50% during the per-
iod of July to October [22] favoring humid and moist habitats [23].
A. baumannii was frequently reported in times of war, such as in
Afghanistan and Iraq [24]. It was revealed that morphine used as
analgesic in battlefields potentiates the growth of A. baumannii
infections rather than trauma itself [25]. Not only in times of war
did A. baumannii prosper, but also in natural disasters such as the
1999 Marmara earthquake aftermath [26] and Asia’s tsunami in
2004 [27]. In general, patients at risk are those who are immuno-
compromised, elderly, premature neonates, and patients that had
recently undergone surgery or experienced a major trauma or were
previously admitted to contaminated ICUs [28,29]. Smoking and
alcohol abuse makes patients more prone to community acquired
A. baumannii pneumonia, especially in tropical areas [30].3. Therapy and resistance
A. baumannii exhibits a natural occurring resistance to a range
of antibiotics such as Amoxicillin (penicillins), narrow-spectrum
cephalosporins, Ertapenem, Trimethoprim, and Chloramphenicol
[31]. A. baumannii managed to acquire resistance genes against
several classes of antibiotics through the transfer of plasmids,
transposons, and integrons from other Gram-negative bacteria
[32]. All contributed to A. baumannii resistance and the ability to
expel aminoglycosides [19], rifampicin [33], quinolones [34], fluo-roquinolones [35], tetracyclines [36], in addition to some disinfec-
tants [37]. Therefore, different strains of multi-drug resistant
(MDR) A. baumannii arouse in many countries all over the world
and caused memorable outbreaks [38], with remarkable regional
differences [39]. Tigecycline first showed a promising effect against
MDR A. baumannii [40,41]. However, resistance to tigecycline has
been reported since 2007 in Israel [42], and recently worldwide
when used as monotherapy for a long time [43]. Alternatively,
Colistin was found effective against Imipenem resistant A. bauman-
nii. However, its use warranted due to its toxicity, side effects [44],
cross-resistance with the host defenses that lead to the emergence
of hypervirulent strains [45], reported resistance [46,47], and the
worrisome hetero-resistance phenomenon [48]. Few novel classes
of antibacterial agents currently show hope against A. baumannii
such as peptide deformylase inhibitors (PDIs) and LpxC inhibitor,
but they are still under trials with contradictory data [49–51].
The lack of effective treatment against A. baumannii introduced
atypical therapeutic options [52], such as the use of bacteriophages
[53], podophage [54], the intake of levamisole an anti-helminthic
that is potent against Acinetobacter lwoffii [55], the use of nano-
particles generating nitric oxide [56], photodynamic therapy [57],
and radio-immunotherapy. However, safety concerns still arise
against their application [58]. Other methods can render MDR A.
baumannii susceptible such as multidrug efflux inhibitor [59,60],
anti-biofilms [61], quorum quenching [62], interference with the
lipopolysaccharide (LPS) biosynthesis [63], the use of antimicrobial
peptides [64,65], in addition to the use of several botanical prepa-
rations. However, all are still under trials along with reported resis-
tance [66].
A British report highlighted that resistance to antibiotics will
definitely increase regardless of their prescription pattern, adding
societal cost of treatment of around £10 billion every year. This
will impact the future of invasive procedures and surgeries, that
require antibiotics as a standard regimen for prophylaxis [67]. Fur-
thermore, a study revealed that patients infected with Imipenem‐
resistant A. baumannii had longer hospital stay of about 21 days
and added an amount of $334,516 to hospital charges [68], with
an increase in mortality rates by 25% in general hospital population
and 50% in ICUs [69]. In a survey established in European countries
from 2003 to 2009, A. baumannii showed to cause mortalities rang-
ing from 3% to as high as 67% [70]. Thus, prevention right from the
start has become a necessity.4. Control and immunostimulants
The previous data declares a war whoop against superbug A.
baumannii. The increased resistance of chemotherapeutics to both
conventional and last resort antibiotics necessitates prevention.
Infection control is an important pillar in patient care excellence
especially ICUs residents, and is a key factor to decrease nosoco-
mial infections in the society and maintain antibiotic stewardship
[71]. A recent study came to a shocking conclusions that the
gowns, gloves, and unwashed hands of health care providers them-
selves are frequently contaminated with MDR A. baumannii acting
as reservoirs in the ICUs [72–74]. When A. baumannii colonizes the
respiratory tract, it can disseminate horizontally by droplet infec-
tion to as far as 22-feet [75]. In addition to that, 25% of the hospital
environment had persistent contamination for months even after
multiple-cleaning treatments [76], due to its biofilm formation
ability [77]. Although new approaches arose to control the biofilm
formation of Acinetobacter [78–80], however they are all under pri-
mary trials. All these facts urge researchers to be directed towards
immunotherapeutics as a lifebuoy to unmet medical needs.
Immunotherapies include non-specific, passive and active
immunization.
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that proved to decrease the risk of A. baumannii septicemia and
VAP [81]. while the use of gaseous nitric oxide probiotic patch
demonstrated a significant antimicrobial efficacy against A. bau-
mannii [82]. Furthermore, c-di-GMP (30,50-cyclic diguanylic acid)
showed an immuno-modulatory effect and induced chemokines
associated with enhanced neutrophil recruitment in the lungs
[83]. It was found that patients admitted to hospitals were colo-
nized within the first 24 h and a significant number of them devel-
oped nosocomial respiratory infections [84]. Therefore, efficient
diagnostic tools play a vital role in the early identification and con-
trol of A. baumannii [85]. Thus, this gives a rationale for nosocomial
immunotherapies to be administered to patients identified under
the immuno-compromised umbrella [86].
Since A. baumannii was identified in the late 1980’s, the first
trial for passive immunization appeared 20 years later in India
[87]. However, the emergence of MDR A. baumannii progressed at
a fast pace as a result of its high persistence in the hospitals’ envi-
ronment, and the inability of antibiotics to cope with the increas-
ing resistance. That’s why starting from 2010 several individual
groups in Spain [88], USA [89,90], Iran [91], Australia [92], and
China [93] started to work extensively on both passive and active
immunization against A. baumannii. Starting from 2013, several
researchers adopted the idea of solving the A. baumannii problem
by vaccination in particular [94–96]. Meanwhile others recom-
mended the trend of ‘‘thinking out of the box” [97], by using new
chemo-immuno-therapies or unraveling new epitopes for the
pathogen [98]. Recent studies confirmed that the pure antigens eli-
cit a more potent immune response [99]. Therefore, other parties
concentrated on the use epitopes’ mapping techniques [92], espe-
cially the in silico computational ones [100] to reveal novel potent
epitopes. They proposed phospholipase D [101], outer membrane
protein BamA [102] and FilF [103], vesicle’s outer membrane pro-
teins OmpK, FKIB and Ompp1 [104], outer membrane protein
nuclease NucAb [105], Pili subunit hemaglutinin [106], and the
functional exposed amino acid BauA [107] as new vaccine candi-
dates. Simultaneously, a coupled mapping procedure that uses
Western blot and mass spectrum techniques proposed OMPs as
major epitopes in human sera [108]. Moreover the study of the role
of the Acinetobacter surface antigen protein (SurA1) in virulence
introduced its application as a vaccine candidate [109]. Another
approach proposed glyco-conjugates as vaccine and diagnostic
tools for A. baumannii [110].5. Passive immunization
Different antisera preparations from bacterial cell components
were evaluated for their potency to neutralize the invading patho-
gen; those might be life-saving in case of acute infections or in
time of outbreaks.5.1. Antisera against whole cells
In 2010 McConnell et al. [88] started to apply whole cell multi-
antigen preparations to raise protective polyclonal hyperimmune
serum against A. baumannii. The formalin Inactivated A. baumannii
Whole Cell (IWC) combined with an adjuvant was used to vacci-
nate mice. The produced antiserum was able to reduce the bacte-
rial load in the spleen post-infection by 1000-fold, which was
sufficient to protect the infected mice, prevent A. baumannii’s dis-
semination, and increase the mice’s survival rate. The Outer Mem-
brane Complexes (OMC) was found to be a valuable complex of
antigens, composed of surface proteins on the outer membrane
of A. baumannii. One year later, the same research group [111]
proved that the polyclonal hyperimmune serum raised againstsonicated OMC prevented the rise of escape mutants, and elimi-
nated A. baumannii from all the immunized mice. Simultaneously,
Huang et al. [93] demonstrated the eminent role of antisera raised
against outer membrane vesicle (OMV) to control Acinetobacter.
5.2. Polysaccharide antisera
Poly-N-acetyl-b-(1-6)-glucosamine (PNAG) is a conserved sur-
face associated exopolysaccharides that are crucial in the mainte-
nance of biofilms integrity under stressful conditions and
protects A. baumannii against innate host defenses [112]. A passive
immunization attempt was done with a synthetic oligosaccharide
that mimics PNAG conjugated to tetanus toxoid (TT). The raised
antisera were able to induce opsonization against several clinical
isolates of MDR A. baumannii, and reduced burdens in infected tis-
sue especially in cases of pneumonia. However, Anti-PNAG sera
showed to be highly specific to only PNAG positive strains even
in minute amounts [90]. PNAG based immunization was named
the ‘‘magic bullets” of the 21st century as PNAG is a basic compo-
nent of biofilm in MDR bacteria involved in both community and
nosocomial infections such as Staphylococcus aureus, Escherichia
coli and A. baumannii. With these promising facts, a monoclonal
preparation against PNAG is already in phase II studies to be mar-
keted soon [113,114]. Although, passive immunization might be
considered a golden treatment in the case of acute infection when
outbreaks rise, polysaccharide active vaccination is not preferred
due to its ability to induce T-cell independent response, and its
inability to induce memory cells unless conjugated to a protein
[114,115].
The K1 capsular polysaccharide (CPS), is rich in polysaccharides
of trisaccharide repeated units, consisting of three pyranose resi-
dues. The K1 capsule proved its importance only recently; when
A. baumannii mutants were used to unravel its role in evading
the host immune defenses by protecting it against complement,
opsonization, and phagocytosis [115]. Its high polysaccharide con-
tent helps in the host-adherence process, helps in the delay of bac-
terial clearance from the host tissues, and is a requisite for survival
within the host soft tissues during infection [116]. The seropreva-
lence of the K1 capsule in different A. baumannii strains reached
only 13% [115]. The monoclonal antibodies (mAb) raised against
K1 capsule of AB307-0294 strain in rat initiated opsonization with
a marked increase in neutrophil-mediated bactericidal activity,
along with a significant 4-logdecrease in the bacterial load of the
infected soft tissues. The use of K1 capsule in immunization is safe,
as it offers an immunogenic response with no clues of cross-
reactivity with human epitopes. However, K1 capsule antiserum
has a drawback of being serotype specific [115].
5.3. Protein based antisera
Acinetobactertrimeric autotransporter (Ata) is a surface protein
composed of a long peptide with an N-terminal, a surface-exposed
passenger domain, and a C-terminal domain encoding for a 4-b
strands found in the outer membrane of A. baumannii. Ata has a
role in biofilm formation, and enhances the bacterial adhesion to
the host’s cells. Therefore, it facilitates survival, and enhance viru-
lence of the pathogen [117]. The anti-recombinant Ata were able to
impair Ata’s binding to collagen type IV of the host’s cells in both
immunocompetent and immunocompromised neutropenic mice.
It promoted complement-dependent bactericidal killing activity,
enhanced both phagocyte-dependent and -independent killing,
protected the challenged mice from A. baumannii pneumonia,
and increased survival rates [89]. Despite anti-Ata proved to
decrease the virulence and colonization, the murine model remains
a poor experimental host for A. baumannii [118]. Although, Ata is a
well-defined protein [111], in-depth analysis revealed that the
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threshold level of Ata expression, which is a limitation against
low-producing Ata strains [89]. Unlike other proteins, the Ata epi-
tope is conserved among several strains, which makes it a valuable
candidate [89,119].
The Iron Regulated Outer Membrane Proteins (IROMP) are low
molecular weight catechol siderophores, having high affinity to
chelate iron. They are composed of four outer membrane proteins,
with molecular weights ranging from 77 kDa to 88 kDa. They have
a vital role in A. baumannii virulence and proliferation, and in iron
acquisition specifically in iron deficient environments [17]. Anti-
IROMPs are promising against homologous A. baumannii in vitro.
Immunization was achieved through the blocking of siderophore-
mediated iron acquisition; thereby inhibiting growth, which in
turn demonstrated both bactericidal effect ranging from 80% to
90%, and increased complement-mediated opsono-phagocytic
activity reaching up to 6–8-fold [87]. However this study was crit-
icized as the researchers did not measure the direct bactericidal
effect in tissues, but rather the in vitro uptake of bacteria by
opsonization in poly-morpho-nuclear cells (PMNs) [89]. Added to
that, IROMPs only develop in iron-depleted environments which
might be a limiting factor as a broad spectrum passive immuniza-
tion approach due to its iron-dependency.
The candidate outer membrane protein A (OmpA) is a part of
the bacterial surface outer membrane, referred to as Omp36, hav-
ing a major role in pathogenesis. It adheres to the host cells in early
infection stages and activates surface cell death receptors. Then, it
localizes in the mitochondria inducing pro-apoptotic molecules
that triggers a cascade of reactions leading to eventual cell death
[120]. When perspective A. baumannii antigens were screened in
a natural systemic infection, OmpA was identified as a primary epi-
tope target of humoral immune response. Resistance of A. bauman-
nii strains to the host’s complement system in serum, were linked
mainly to OmpA when it binds to factor H (a main regulator to the
serum alternative complement-pathway) [121]. Its structure is
more than 99% conserved among clinical strains from different
infection sites and P89 conserved within other A. baumannii
strains, with low homology compared to the human proteome.
Raised anti-recombinant OmpA antibodies conferred protection
through enhanced opsono-phagocytosis but not the complement
mediated killing against MDR A. baumannii, since anti-OmpA was
not able to restore the complement system activity against A. bau-
mannii [119]. Further research on antisera against OmpW [122],
Omp22 [123], and outer membrane nuclease (NucAb) [105] of
Acinetobacter demonstrated their role to improve survival in exper-
imental animals.6. Active immunization
The use of different antigens as vaccine candidates in healthy
models paved its way to prevent infections due to A. baumannii,
which include the followings.6.1. Whole cell vaccines
Mice were injected by formalin Inactivated Whole A. baumannii
Cells (IWC), formulated with aluminum phosphate as adjuvant
(Adjuphos). The intramuscular injection of the IWC preparation
resulted in a rapid robust of antibody titers. The immunized mice
had less bacterial burdens in the infected tissues, and a reduced
production of pro-inflammatory cytokine serum levels of IL-1b,
TNF-a, and IL-6 that are normally associated with sepsis. Thus, it
helped to secure high survival rates in vaccinated mice [88]. A
more recent study proved that the vaccine could be administered
intranasally as well [124] and that the antibiotic exposed bacterialcells produce a potent vaccine [125]. IWC are easy to prepare, inex-
pensive, and does not require expensive denaturation of antigens,
that may induce conformational changes of the epitopes. Added
to that, it was shown that A. baumannii while acquiring resistance;
has the ability to down-regulate the surface expression of certain
surface membrane protein. IWC vaccine was able to generate
hyper-immune antibodies against its multi-antigenic components,
mostly those belonging to the outer membrane, thus providing
diverse protection against several A. baumannii strains. However,
safety remains a concern with IWC use as incomplete inactivation
of the bacterial cell which might initiate infection or the possibility
of being contaminated with pyrogenic endotoxin during injection
[88]. Researchers overcame this obstacle by the production of an
IWC vaccine based on LPS deficient A. baumannii strain. The vaccine
proved to induce a protective level of immunoglobulins, and
reduced the pro-inflammatory cytokines [126].
The sonicated Outer Membrane Complex (OMC) was formu-
lated with Adjuphos, and used as a vaccine. The OMC vaccine
was confirmed to be highly reproducible, and can limit post infec-
tion pro-inflammatory cytokines associated with septic shock. It
was able to increase IFN-c, to be highly potent and heterologous,
and reduced the bacterial burdens in tissues by 105-fold. The
OMC preparation elicited a rapid IgG and IgM response against
the bacterial OMP only (not the other bacterial components such
as the LPS). The humoral response was able to provide a protective
immunity with just a single vaccine dose in as few as 6 days post-
immunization and was maintained for 21 days. This aspect can be
life-saving in case of outbreaks or critical conditions. However,
safety concerns still arise about the possible endotoxin contamina-
tion [111].
Outer Membrane Vesicles (OMV) are secreted by A. baumannii
during growth. They are spherical, non-viable, and acellular nano-
vesicles that contribute to colonization during infection [127].
OMVhas a role in spreading antibiotic resistance genes and quorum
sensing ability [17]. A hundred and thirteen different proteins were
identified and found to be packed within OMV, majorly consisting
of OmpA, other outer membrane proteins, CarO protein, tissue
degrading enzymes, as well as, LPS and nucleic acids [128]. Mice
were vaccinated with OMV formulated with Adjuphos, then
boosted after 3 weeks by the same preparation. It was found that
the IgG increased by 60-fold, bacterial tissue burdens were reduced
by 106-fold, and the pro-inflammatory cytokines IL-6 and IL-1b
decreased post-infection [129]. OMV vaccine offered a full heterol-
ogous protection to immunized mice against several A. baumannii
strains including pan-resistant isolates, which is a perk compared
to subunit vaccines that can become ineffective in the case of pro-
teins down-regulation observed in A. baumannii. The vaccine con-
ferred protection in both pneumonia and sepsis models [93]. The
extraction process of OMV involves the use of detergents to reduce
the endotoxin content. Although the detergents might deplete its
active soluble antigens, it still holds the benefit of rapid production
requiring only filtration compared with the manufacture of recom-
binant single antigen vaccines. OMV being acellular, has a compet-
itive advantage over inactivated whole cell as it is much safer and
produces less adverse toxic events, although endotoxin is still pre-
sent and might trigger safety issues [129]. This may be counted as a
defect for all other whole cell vaccines, since the components are
not standard between lots (81).
6.2. Pure protein based vaccines
In 2011, a mixture of pure proteins majorly OMPs and fimbrae
proteins was patented as effective vaccine against A. baumannii
[130]. Later on, in silico mapping confirmed the potency of OmpA
type 1 in particular [131]. The preparation of recombinant OmpA
(rOmpA) with aluminum hydroxide as adjuvant in a dose of
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increase in mice survival rates by decreasing bacterial tissue bur-
dens, and induced high anti-OmpA IgG antibodies titers that
soared by increasing the dose up to 30-fold [132]. Although, it
was proposed that the pure OmpA is more favorable than the com-
plex IWC, the broad spectrum immune responses to other proteins
within the IWC cannot be denied [133]. More recently, a vaccine
was developed by being formulated with nano-chitosan as adju-
vant, and proved good efficacy [134]. OmpA vaccines are very
promising as they are highly reproducible, easily to be manufac-
tured commercially, and safer than the whole complex prepara-
tions [132]. However, when it is in a purer OmpA form it
becomes insoluble making its routes of delivery hard [135]. Further
research on the Omps such as Omp22 [123], OmpW [122], as well
as the epitope mapped outer membrane nuclease (NucAb) [105]
and the selected Omps [104] proved their potency as vaccine
candidates.
The candidate Bap protein is a high molecular weight 854 kDa
and one of the most acidic proteins, found on the surface of A. bau-
mannii. It was identified as an important key regulator of biofilm
maturation and maintenance of the biofilm structure, thickness,
and volume. The Bap’s presence increases the bacterial cell
hydrophobicity which enhances its adherence to the host cells
and helps the bacteria to dodge phagocytes [136]. Active immu-
nization with Bap targets the most virulent character of A. bauman-
nii and deprives it from biofilm formation, with an added benefit of
being 43% conserved among isolates. Recombinant Bap subunit
was prepared, emulsified with complete Freund’s adjuvant, and
used to vaccinate mice. Immunized mice exhibited high IgG anti-
body titers, with a complete bacterial clearance from the infected
tissues, which in turn increased mice survival rates. Bap subunit
vaccine has around 20 antigenic determinants and 55 discontinu-
ous B-cell epitopes, hence demonstrated immune-dominancy
[91]. Further research on the combination of Bap with OMV or
OmpA of Acinetobacter proved an augmented potency versus the
individual components [137]. More recently, the previously
mapped acinetobactin (BauA) [107] proved its importance as a pro-
phylactic agent against Acinetobacter [138].
7. Comment
A. baumannii has risen as an opportunistic resistant superbug
causing outbreaks worldwide, which resulted in high morbidity
and mortality rates especially to prone patients. A. baumannii is
not easily identified, but rather requires sophisticated and time-
consuming equipment, when time is of the essence to save lives.
A. baumannii is also hard to manage due to its fast acquisition of
antimicrobial resistance; already putting an end to the antibiotic
golden era. New antibiotics inventory became depleted against A.
baumannii invasion, while all alternative therapies are still under
development, requiring years to be available on the market. Thus,
breaking the vicious cycle right from the start makes an ideal ratio-
nale side-by-side with infection control.
Indeed the pioneer work of the Australian group to use in silico
techniques to screen the antigenic determinants of A. baumannii
was the right step to find the effective epitopes, but was rather an
incomplete one, since A. baumannii has some immune-dominant
antigens thatmay overshadow other effective ones in the pathogen.
Moreover, in silico basedmethods only predict the protein epitopes,
but never the polysaccharide ones. Therefore, the bare application of
those proposed epitopes may be of limited value, and further inves-
tigation by binding techniques are necessary to design a potent vac-
cine against A. baumannii. It is clear nowadays that the epitope
screening protocols are crucial, sincemiss-guided empirical vaccine
production is a trial and error challenge.In general the ideal immunotherapy candidate antigen against
A. baumannii should possess important qualities. These qualities
include being protective for the host, highly prevalent, conserved
among different strains of A. baumannii to deliver broad spectrum
protection (heterologous), highly reproducible, cheap, and surface-
exposed. As well as being able to remain stable and soluble after
preparation or in its recombinant form, and induce a rapid robust
humoral antibody titers yet having a sustained cellular response.
They should also reduce the incidence of septic shock, and can alle-
viate the pro-inflammatory cytokines. It is important as well that
the ideal antigen is able to protect immunocompromised candi-
date, to be of well-defined components in term of quantity and
identity, and last but not least to be safe for human use. Moreover,
that candidate should have a proven efficacy for both passive and
active immunization, which is an additional privilege. That’s why
the evaluation of any immune-preparation should fulfill these
criteria.
Several experimental attempts against whole cell, polysaccha-
rides or protein preparations generated therapeutic antiserum
against A. baumannii. They all conferred protection to laboratory
animals; the majority increased opsonization, reduced the bacte-
rial burden in tissues, and prevented its dissemination. The use
of K1-CPS to produce mAb against A. baumannii was expensive
and limited to only 13% of CPS-positive isolates. The use of the
anti-IROMP was not practical since it exhibited a limited homolo-
gous protection for the pathogen grown in iron depleted environ-
ments. Although, the antiserum raised against r-Ata was the only
preparation that prevented the bacterial adherence, the response
was highly dependent on the Ata level expressed by the bacterial
cells. Yet, the anti-Ata showed to be active in both immune-
competent and immune-compromised models, the applied murine
model is a poor experimental host.
Despite PNAG antiserum is the only preparation that went
through clinical trials, it did not confer heterologous protection
and required a complicated conjugation step with a protein to eli-
cit a remarkable antibody titer as being a hapten. This increases the
production cost and may alter the immunogenicity of PNAG. The
OmpA is a conserved antigen that generates a sufficient amount
of antibodies, as being a protein in nature. The anti-OmpA was safe
and provided a heterologous protection. However, the facts that A.
baumannii undergoes protein down-regulation (such as all other
Omp-related preparations), and that r-OmpA is not sufficiently sol-
uble thus limiting the attractiveness of anti-OmpA as a powerful
immunotherapeutic preparation. Moreover, none of the above
antisera protected the host from septic shock, such as the effect
conferred by the polyclonal preparation raised by the whole cell
preparations. The IWC, OMV and OMC preparations are the cheap-
est and their immunogenic determinants do not undergo any
denaturation processes during preparation. However, LPS toxicity
remains a concern during antibody generation, which may be
resolved by a mild acid hydrolysis detoxification. While the use
of the whole cell isolates vaccine that lack LPS may be useless,
since the whole cell antisera will lose the potency to protect the
host from the septic shock.
All the up-to-date vaccine formulations conferred high cellular
and humoral immune response, protection from both homologous
and heterologous bacterial challenges, and hence increased sur-
vival rates among experimental animals. The cost of production
of recombinant Omps and Bap is relatively higher, and the prepa-
rations might lose their potency in case the pathogen develops pro-
tein down regulation mechanisms. Since direct extraction is not
practical, cloning techniques were adapted to produce the Omps
and Bap. Unfortunately; these cloning and refolding techniques
may alter the conformational structure of the produced proteins
and render the preparation insoluble. This will affect the immune
58 T.A. Ahmad et al. / Trials in Vaccinology 5 (2016) 53–60response potency which is highly dependent on the native 3-
dimentional structure of the produced protein.
On the other hand, the whole cell vaccine preparations are very
cheap to prepare, broad spectrum, and do not require any interven-
tion during production that might denature the structure of the
proteins. Added to that, the whole cell vaccines reduce the post
inflammatory cytokines, generated antibodies against the LPS,
and hence avoid the septic shock cascade. Although, IWC are less
safe when used in human beings, OMC and OMV overcame this
problem as being acellular. In addition, OMC possesses a unique
role in eliciting a rapid protective humoral immune response in
less than six days from administering the first dose. This privilege
favors’ OMC as the best choice to be used in the case of outbreaks;
especially that the antiserum raised against it, has a proven
potency to control active bacterial infections. Moreover, OMC can
induce the production of the IFN-c that enhances non-specific
NK cell activity, which is an advantage for immunocompromised
patients residing ICUs. However, the OMC is not powerful enough
to elicit antibodies against the LPS, due to the overshadowing
effect. Whereas, OMV has the potency to highly increase the
immunoglobulin titers against A. baumannii, and remarkably
reduced the bacterial burden from infected tissues. Therefore, a
combined vaccine between OMV and OMC would be an ideal
choice. However, concerns regarding the endotoxic impurities
remain as safety barriers.
It is well known that the toxicity of the LPS is exclusively due to
the lipid A portion in the molecule. However, the majority of the
classical methods used to remove endotoxins depend on deter-
gents that fully remove the LPS molecule and may also deplete
the vaccine from its other soluble active antigens. Simultaneously,
other researches depend on the use of LPS-deficient isolates. Thus
the presence of the polysaccharide portion of the LPS in the vaccine
induces a broad protective spectrum against the pathogen’s endo-
toxin, lowers the pro-inflammatory cytokines, and in turn reduces
the mortality due to septic shock. This point is a highly critical
point, since LPS is a necessary component in a powerful vaccine
against A. baumannii, while its toxicity might be fatal. That’s why,
further studies should be directed towards the evaluation of a
new method that depends on developing the detoxification of
the OMC/OMV vaccine by gentle lipolytic methods, or the produc-
tion of natural self-conjugated vaccines between the detoxified LPS
and the OMPs, as previously described by the author’s research on
Klebsiella pneumoniae. This later one has the advantage of eliciting
a longtime thymus dependent cellular immune response against
the conjugate individual components, as well as being of well-
defined standard ingredient in terms of quality and quantity.
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